Prelude Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Prelude Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-466	Closed	-$33K	–	2129
2020 Q2	$33K	Buy	466 +62	+15%	+$3.93K	﹤0.01%	1267
2020 Q1	$18K	Sell	404 -303	-43%	-$17.2K	﹤0.01%	1014
2019 Q4	$46K	Buy	+707	New	+$47.2K	﹤0.01%	1366
2018 Q4	–	Sell	-90	Closed	-$15K	–	2000
2018 Q3	$15K	Buy	+90	New	+$13.6K	﹤0.01%	1372
2017 Q3	–	Sell	-3,163	Closed	-$240K	–	1780
2017 Q2	$240K	Buy	+3,163	New	+$221K	0.02%	523
2016 Q2	–	Sell	-739	Closed	-$49K	–	1660
2016 Q1	$49K	Buy	+739	New	+$44.9K	0.01%	978
2015 Q3	–	Sell	-401	Closed	-$25K	–	1637
2015 Q2	$25K	Buy	+401	New	+$21.9K	﹤0.01%	1312
2015 Q1	–	Sell	-1,122	Closed	-$37K	–	2055
2014 Q4	$37K	Buy	1,122 +160	+17%	+$5.21K	0.01%	1460
2014 Q3	$28K	Sell	962 -9,618	-91%	-$319K	﹤0.01%	1665
2014 Q2	$411K	Buy	+10,580	New	+$429K	0.05%	449

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Prelude Capital Management's LGND Position: Q3 2020 in Review

Prelude Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 466 shares — an estimated $33K sold.

Prelude Capital Management first reported a position in LGND in Q2 2014 and held it in 10 quarters. The position peaked at $411K in Q2 2014. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

Prelude Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Prelude Capital Management sold 466 Ligand Pharmaceuticals shares in Q3 2020, an estimated $33K.
Prelude Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 10 quarters.
Prelude Capital Management's Ligand Pharmaceuticals position peaked at $411K in Q2 2014.
252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.